. 2013 Jul 24;6:931–942. doi: 10.2147/OTT.S33532

Table 2.

Clinical trials of nimotuzumab in combination with radiation and chemoradiation in pediatric high grade glioma

Trial number (country)	Indication	Phase	Study design	Main results	Publications (reference)
OSAG 101-BSC-05 (Germany)	DIPG	III	Nimotuzumab + RT	ORR: 9.8% DCR: 75.6% PFS-6 months: 33.3% MSV: 9.4 months	Fleischhack et al⁴¹
IIC RD EC097 (Cuba)	DIPG	II	Nimotuzumab + RT	DCR: 75.0% (6/8)	Crombet et al⁴²
Not available (Italy)	DIPG	II	Nimotuzumab + RT + vinorelbine	PFS-6 months: 90%	Massimino et al³⁵

Abbreviations: DCR, disease control rate; DIPG, diffuse intrinsic pontine glioma; MSV, median survival; ORR, objective response rate; PFS, progression free survival; RT, radiotherapy.